Zobrazeno 1 - 10 of 35 pro vyhledávání: '"XingNong Ye"'
1
Akademický článek
Inactivated vaccine dosage and serum IgG levels correlate with persistent COVID-19 infections in hematologic malignancy patients during the Omicron Surge in China
Autor: Li Ye, Ye Yang, Xuewu Zhang, Lu Wang, Li Zhu, Xia Li, Yile Zhou, Xiaolong Zheng, Xinping Zhou, Yanling Ren, Liya Ma, Gaixiang Xu, Chunmei Yang, Huafeng Wang, De Zhou, Min Yang, Xingnong Ye, Juying Wei, Wenjuan Yu, Jiejing Qian, Yinjun Lou, Wanzhuo Xie, Jian Huang, Haitao Meng, Jie Jin, Hongyan Tong
Publikováno v: BMC Infectious Diseases, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Purpose The essence of this scholarly work was to carefully outline the key factors intensifying the virulence and protracted contagion of COVID-19, particularly among individuals afflicted with hematologic malignancies (HM), in an epoch pre
Externí odkaz: https://doaj.org/article/6c19244eca03404d9f80f551944d54e1
Zobrazit plný text záznamu
2
Akademický článek
Continuous therapy in HHV-8 negative Multicentric Castleman Disease and prolonged progression-free survival
Autor: Yi Liu, Xuejiao Yin, Shengnan Ding, Jiaying Ge, Liya Ma, Min Yang, Xuxia Luo, Chengli Zhong, Sishi Fang, Qiumei Yao, Li Zhu, Wenjuan Yu, Liping Mao, Juying Wei, Xingnong Ye, De Zhou, Hongyan Tong, Haitao Meng, Jie Jin, Liangshun You
Publikováno v: Journal of Hematology & Oncology, Vol 17, Iss 1, Pp 1-5 (2024)
Abstract The optimal treatment endpoints and duration of continuous therapy for multicentric Castleman disease (MCD) remain controversial. We retrospectively analyzed data from 123 patients with Human Herpesvirus (HHV)-8 negative MCD. We demonstrated
Externí odkaz: https://doaj.org/article/287d1a9727464dbfa8623b22295642e2
Zobrazit plný text záznamu
3
Akademický článek
A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With SF3B1 Mutation
Autor: Liya Ma, Bin Liang, Huixian Hu, Wenli Yang, Shengyun Lin, Lihong Cao, Kongfei Li, Yuemin Kuang, Lihong Shou, Weimei Jin, Jianping Lan, Xingnong Ye, Jing Le, Huyi Lei, Jiaping Fu, Ying Lin, Wenhua Jiang, Zhiying Zheng, Songfu Jiang, Lijuan Fu, Chuanyong Su, XiuFeng Yin, Lixia Liu, Jiayue Qin, Jie Jin, Shenxian Qian, Guifang Ouyang, Hongyan Tong
Publikováno v: Frontiers in Oncology, Vol 12 (2022)
The outcomes of myelodysplastic syndrome (MDS) patients with SF3B1 mutation, despite identified as a favorable prognostic biomarker, are variable. To comprehend the heterogeneity in clinical characteristics and outcomes, we reviewed 140 MDS patients
Externí odkaz: https://doaj.org/article/0027be8f33ee4b47aaabec93143fea60
Zobrazit plný text záznamu
4
Akademický článek
Low Humoral Immune Response and Ineffective Clearance of SARS-Cov-2 in a COVID-19 Patient With CLL During a 69-Day Follow-Up
Autor: Xingnong Ye, Xiaofang Xiao, Bin Li, Weigang Zhu, Youjiang Li, Jianguo Wu, Xin Huang, Jingxia Jin, Dan Chen, Jie Jin, Jian Huang
Publikováno v: Frontiers in Oncology, Vol 10 (2020)
Background: A recent outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), which began in Wuhan, China, with a high level of human-to-human transmission has been reported. There are limited data available on Coronavirus Disease 20
Externí odkaz: https://doaj.org/article/16302818a4bc443794b908b4bab6d56d
Zobrazit plný text záznamu
6
All-trans retinoic acid enhances the cytotoxic effect of decitabine on myelodysplastic syndromes and acute myeloid leukaemia by activating the RARα-Nrf2 complex
Autor: Lu Wang, Qi Zhang, Li Ye, Xingnong Ye, Wenli Yang, Hua Zhang, Xinping Zhou, Yanling Ren, Liya Ma, Xiang Zhang, Chen Mei, Gaixiang Xu, Kongfei Li, Yingwan Luo, Lingxu Jiang, Peipei Lin, Shuanghong Zhu, Wei Lang, Yuxia Wang, Chuying Shen, Yueyuan Han, Xiaozhen Liu, Haiyang Yang, Chenxi Lu, Jie Sun, Jie Jin, Hongyan Tong
Publikováno v: British Journal of Cancer. 128:691-701
Background Decitabine (DAC) is used as the first-line therapy in patients with higher-risk myelodysplastic syndromes (HR-MDS) and elderly acute myeloid leukaemia (AML) patients unsuitable for intensive chemotherapy. However, the clinical outcomes of
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85f8d98d05b54cdbab1ee7c2395d5a9d
https://doi.org/10.1038/s41416-022-02074-0
Zobrazit plný text záznamu
7
Clinical features and next-generation sequencing landscape of essential thrombocythemia, prefibrotic primary myelofibrosis, and overt fibrotic primary myelofibrosis: a Chinese monocentric retrospective study
Autor: Lan Zhang, Xingnong Ye, Shuna Luo, Xiaofei Xu, Shengjie Wang, Keyi Jin, Yan Zheng, Xiaoqiong Zhu, Dan Chen, Jie Jin, Jian Huang
Publikováno v: Journal of Cancer Research and Clinical Oncology. 149:2383-2392
Since prefibrotic primary myelofibrosis (pre-PMF) was recognized as a separate entity in the 2016 revised classification of MPN differed from essential thrombocythemia (ET) or overt fibrotic primary myelofibrosis (overt PMF), it has been a subject of
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e9ad8ccc6c44415269cf8affc4d8f94
https://doi.org/10.1007/s00432-022-04067-1
Zobrazit plný text záznamu
8
Venetoclax Plus '2 + 5' Modified Intensive Chemotherapy with Daunorubicin and Cytarabine in Fit Elderly Patients with Untreated De Novo Acute Myeloid Leukemia: A Single-Center Retrospective Analysis
Autor: Huafeng Wang, Yiyi Yao, Liping Mao, Yinjun Lou, Yianlin Ren, Xingnong Ye, Min Yang, Liya Ma, Yi Zhang, Yile Zhou, Xin Huang, Yungui Wang, Huan Xu, Hongyan Tong, Hong-Hu Zhu, Jie Jin
Publikováno v: Blood. 140:3350-3351
Background Therapeutic options remain limited for elderly acute myeloid leukemia (AML) considering the poor tolerance to intensive chemotherapy. Venetoclax in combination with modified intensive chemotherapy has been shown achieved significantly impr
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a7d28de937bd556d1ecbe96aa6c1c24
https://doi.org/10.1182/blood-2022-165738
Zobrazit plný text záznamu
10
Ruxolitinib Plus Decitabine Effectively Treats Myelodysplastic Syndrome/Myeloproliferative Neoplasm, Unclassifiable, by Decreasing the Variant Allele Frequency of KRAS
Autor: Shuna Luo, Cai Wu, Xiaofei Xu, Dan Chen, Xingnong Ye, Jian Huang, Xiaoqiong Zhu, Jingxia Jin, Mengli Zheng, Yan Zheng
Publikováno v: OncoTargets and Therapy. 13:10143-10148
Myelodysplastic syndrome/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U) is a subtype of MDS/MPN that exhibits a combination of the features of both MDS and MPN. To date, no curative treatment is available for MDS/MPN-U; however, previous stu
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e6082840ea8ec769ed65e8d690bbc074
https://doi.org/10.2147/ott.s272207
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje